Recent content by Cloudburst

I completely agree with you and I think the conditional market approval will be exactly that. If they had a product I don’t think they’d wait the full seven years but I cannot see this being available anywhere outside of Japan until the usual Phase 3 process is complete.

I think the dispute stretched the relationship but it looks to still be on course; no separation of the partnership was announced and as they’re listed companies they would need to report that. This is a product I think will be available to some extent within twelve months; my only concern is to...

The Japanese financial year runs 1 April - 31 March so if results come in Q2, expect then between July-September.

If that’s correct then fair enough; but I think the difference here is the intention is evidently to perform treatment in their purpose built centre. At least early on. I also think there’s quite a lot of discretion to the regulator as to what is required. I’m sure it’s plausible that a...

I’m a lawyer (not in this specialism but I’ve had a look at the legislation) and having read it, I t’s difficult to see how this could be commercialised globally given they need to register and check up on patients; I doubt even if they could go global, from a logistical standpoint it would...

Is it not correct that if they bring it to market under the new laws that any patient must be monitored, etc almost as if they were an extension to the trial? If so it’s going to be difficult for this to be available outside of the immediate vicinity of the Centre they have opened.

I would have thought the fastest way to profit would to train reputable surgeons globally (subject to relevant domestic approval) and charge for the cloning process. Almost like licensing your product; after all that’s the USP. New here by the way, long time lurker.